A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSV

PHASE1TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 15, 2024

Primary Completion Date

September 3, 2024

Study Completion Date

September 3, 2024

Conditions
Respiratory Syncytial Virus Infections
Interventions
DRUG

Placebo

Placebo

DRUG

Active

Sisunatovir

Trial Locations (9)

2013

University of Witwatersrand (WITS) - Vaccines and Infectious Diseases Analytics (VIDA), Johannesburg

5219

Monti Clinical Research Centre, Mdantsane

63110

Washington University School of Medicine, St Louis

90027

Kaiser Permanente Los Angeles Medical Center, Los Angeles

Kaiser Permanente, Los Angeles

457-8511

Kojunkai Daido Hospital, Nagoya

899-2503

Nintenkai Kagoshima Children's Hospital, Hioki

400-8506

Yamanashi Prefectural Central Hospital, Kofu

534-0021

Osaka City General Hospital, Osaka

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY